Bharat Biotech has recruited 23,000 volunteers and continued to progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of its COVID-19 vaccine Covaxin across multiple......
Bharat Biotech International Ltd (BBIL) on Monday said it has completed the phase-III and booster dose trials for its intranasal Covid-19 vaccine BBV154, and it has proven to be safe. Photograph:......
Bharat Biotech's Joint Managing Director Suchitra Ella's tweet saying 50 of their employees tested positive for COVID-19 received bouquets and brickbats from netizens, with some saying Covaxin was......
This apart, to further increase capacities, Bharat Biotech has partnered with Indian Immunologicals (IIL) to manufacture the drug substance for Covaxin. The technology transfer process is......
Bharat Biotech on Friday said it has committed to supply over 500 million doses of its COVID-19 vaccine Covaxin to the Centre under the countrywide immunisation programme. ......
The Hepatitis-B vaccine market, which is shared by more than 13 players, has not grown beyond Rs 120 crore (Rs 1.2 billion) against the projected Rs 600 crore (Rs 6 billion) by 2004-05.Retail......
When the Andhra Pradesh government identified biotechnology as one of the engines of economic growth for the state, it came as a surprise for many. After all, Shantha Biotech and Bharat Biotech......
USV, a Mumbai-based Rs 800 crore drug manufacturer with research expertise in small molecules and proteins, recently decided to venture into the lucrative segment of vaccines. For that, it decided......
Unlike many of his peers in corporate houses, Kumar doesn't have an MBA but says that hardly matters, as he has been lucky to have got great on-the-job experience, such as during his stint in Asia......